2,559 Shares in Johnson & Johnson $JNJ Acquired by Caerus Investment Advisors LLC

Caerus Investment Advisors LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,559 shares of the company’s stock, valued at approximately $474,000.

Several other hedge funds also recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Johnson & Johnson in the second quarter valued at $4,877,174,000. Laurel Wealth Advisors LLC increased its position in Johnson & Johnson by 15,040.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after purchasing an additional 7,371,687 shares in the last quarter. Capital International Investors increased its position in Johnson & Johnson by 545.6% during the 3rd quarter. Capital International Investors now owns 3,865,050 shares of the company’s stock worth $716,657,000 after purchasing an additional 3,266,354 shares in the last quarter. Amundi raised its stake in Johnson & Johnson by 19.3% in the 3rd quarter. Amundi now owns 13,354,936 shares of the company’s stock valued at $2,512,719,000 after purchasing an additional 2,163,838 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in Johnson & Johnson by 126.3% in the 3rd quarter. Marshall Wace LLP now owns 3,584,162 shares of the company’s stock valued at $664,575,000 after purchasing an additional 2,000,609 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves ICOTYDE (icotrokinra), J&J’s once‑daily oral IL‑23R targeted peptide for moderate‑to‑severe plaque psoriasis — a first‑in‑class oral alternative to leading injectable IL‑23 therapies that could expand patient access and drive new prescription revenue. US FDA approves J&J’s oral psoriasis pill
• Positive Sentiment: HSBC raised its JNJ price target to $280 (from $265) and reiterated a Buy, citing healthcare strength and likely improved near‑term fundamentals — this adds analyst support and gives upside cushion relative to current levels. HSBC Sees Healthcare Strength, Lifts Johnson & Johnson (JNJ) Price Target
• Neutral Sentiment: Analyst commentary and comparisons (e.g., J&J vs Merck) highlight relative strengths/risks across pipelines and cash flows — useful context but not an immediate catalyst. J&J or Merck? Key Factors Investors Must Weigh Right Now
• Neutral Sentiment: Market watchlists and “stocks to watch” mentions raise visibility but don’t change fundamentals immediately. 4 stocks to watch on Wednesday: T, M, MU, JNJ
• Negative Sentiment: Shares recently pulled back (reports of a slide and lower intraday volume) indicating short‑term profit‑taking despite the positive drug news and analyst upgrade; that pressure likely explains the stock trading down today. Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on JNJ. Bank of America reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 2nd. Leerink Partners upped their price objective on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. Citigroup raised their target price on shares of Johnson & Johnson from $250.00 to $274.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. HSBC boosted their price target on Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Daiwa Securities Group increased their price target on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $236.17.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.4%

Shares of JNJ stock opened at $237.15 on Thursday. The firm’s 50-day simple moving average is $233.95 and its 200-day simple moving average is $207.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71. The firm has a market cap of $571.21 billion, a P/E ratio of 21.46, a PEG ratio of 2.35 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s payout ratio is currently 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.